First quarter with 2% growth in Swiss francs, 7% at constant exchange rates
Group sales increase 2% in Swiss francs and 7% at constant exchange rates, driven by new products, more than compensating for impact of competition from biosimilars
Pharmaceuticals Division sales up 7%, led by Tecentriq, Hemlibra, Ocrevus and Perjeta
Diagnostics Division sales grow 5%, with molecular testing as main contributor
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Switzerland Health